SCHEMBL2853329

SCHEMBL2853329

N#Cc1ccc(C(F)(F)C(F)(F)F)cc1

nearest known ligand 0.59

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
KIF11 P52732 4/20 0.59
PTPN5 P54829 1/20 0.47
CYP19A1 P11511 4/20 0.46
CYP2A6 P11509 2/20 0.42
ALDH1A1 P00352 1/20 0.42
CA12 O43570 1/20 0.42
CA2 P00918 1/20 0.42
CA3 P07451 1/20 0.42
CA6 P23280 1/20 0.42
CA9 Q16790 1/20 0.42
CA14 Q9ULX7 1/20 0.42
TSHR P16473 1/20 0.40
CYP3A4 P08684 1/20 0.40
CYP3A5 P20815 1/20 0.40
NR1H3 Q13133 1/20 0.40
MLYCD O95822 2/20 0.39
LOXL2 Q9Y4K0 1/20 0.38
MMP3 P08254 1/20 0.38
ENPP2 Q13822 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31386831 0.85 KIF11 (0.53) KIF11PTPN5CYP19A1CYP2A6ALDH1A1
SCHEMBL27284292 0.84 KIF11 (0.57) KIF11PTPN5CYP19A1CYP2A6ALDH1A1
SCHEMBL16626137 0.84 KIF11 (0.76) KIF11PTPN5CYP19A1CYP2A6ALDH1A1
SCHEMBL11623557 0.82 KIF11 (0.55) KIF11PTPN5CYP19A1CYP2A6ALDH1A1
SCHEMBL22303438 0.82 KIF11 (0.55) KIF11PTPN5CYP19A1CYP2A6ALDH1A1
SCHEMBL5361628 0.81 KIF11 (0.59) KIF11PTPN5CYP19A1CYP2A6ALDH1A1
SCHEMBL7601631 0.81 KIF11 (0.59) KIF11PTPN5CYP19A1CYP2A6ALDH1A1
SCHEMBL17344731 0.81 KIF11 (0.59) KIF11PTPN5CYP19A1CYP2A6ALDH1A1
SCHEMBL17943228 0.80 CYP2A6 (0.67) KIF11PTPN5CYP19A1CYP2A6ALDH1A1
SCHEMBL524351 0.80 KIF11 (0.86) KIF11PTPN5CYP19A1CYP2A6ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
JP-3109381-A None JP disclosed
US-11925651-B2 TEAD inhibitors and uses thereof Ikena Oncology, Inc. (US) 2024-03-12 US disclosed
US-20230148061-A1 TEAD INHIBITORS AND USES THEREOF THE EHE FOUNDATION 2023-05-11 US disclosed
US-20230148061-A1 TEAD INHIBITORS AND USES THEREOF THE EHE FOUNDATION 2023-05-11 US disclosed
US-11458149-B1 TEAD inhibitors and uses thereof Ikena Oncology, Inc. (US) 2022-10-04 US disclosed
CN-114502540-A TEAD inhibitors and uses thereof 医肯纳肿瘤学公司 2022-05-13 CN disclosed
EP-3976192-A1 TEAD INHIBITORS AND USES THEREOF Ikena Oncology, Inc. (US) 2022-04-06 EP disclosed
WO-2020243423-A1 TEAD INHIBITORS AND USES THEREOF Ikena Oncology, Inc. (US) 2020-12-03 WO disclosed
WO-2020243423-A1 TEAD INHIBITORS AND USES THEREOF Ikena Oncology, Inc. (US) 2020-12-03 WO disclosed
EP-1984322-B1 BENZAMIDE AND HETEROARENE DERIVATIVES HOFFMANN LA ROCHE (CH) 2012-09-26 EP disclosed
WO-2007090748-A1 BENZAMIDE AND HETEROARENE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2007-08-16 WO disclosed
WO-2007090752-A1 ANTHRANILAMIDE/2-AMINO-HETEROARENE CARBOXAMIDE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2007-08-16 WO disclosed
US-20070185058-A1 Heteroaryl and benzyl amide compounds HOFFMANN-LA ROCHE INC. 2007-08-09 US disclosed
EP-1805141-A1 PIPERIDINES AND RELATED COMPOUNDS FOR TREATMENT OF ALZHEIMER'S DISEASE MERCK SHARP & DOHME LTD. (GB) 2007-07-11 EP disclosed
WO-2006043064-A1 PIPERIDINES AND RELATED COMPOUNDS FOR TREATMENT OF ALZHEIMER'S DISEASE MERCK SHARP & DOHME LIMITED (GB) 2006-04-27 WO disclosed
WO-2006043064-A1 PIPERIDINES AND RELATED COMPOUNDS FOR TREATMENT OF ALZHEIMER'S DISEASE MERCK SHARP & DOHME LIMITED (GB) 2006-04-27 WO disclosed
EP-0354297-B1 THIADIAZINES, PROCESS FOR PRODUCTION THEREOF, AND INSECTICIDAL AND ACARICIDAL AGENTS COMPRISING THE THIADIAZINES MITSUI TOATSU CHEMICALS, Inc. (JP) 1992-08-05 EP disclosed
US-5021412-A Protecting agricultural crops MITSUI TOATSU CHEMICALS, INC. (JP) 1991-06-04 US disclosed
JP-H03109381-A FLUORINE-CONTAINING ARYLGUANAMINE COMPOUND AND PRODUCTION THEREOF MITSUI TOATSU CHEM INC 1991-05-09 JP disclosed
EP-0354297-A1 Thiadiazines, process for production thereof, and insecticidal and acaricidal agents comprising the thiadiazines MITSUI TOATSU CHEMICALS, Inc. (JP) 1990-02-14 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230148061-A1 TEAD INHIBITORS AND USES THEREOF TEAD2, TEAD3, TEAD4 KIF11 2459/4885PTPN5 1125/4885CYP19A1 559/4885
US-11925651-B2 TEAD inhibitors and uses thereof TEAD2, TEAD3, TEAD4 KIF11 2459/4885PTPN5 1125/4885CYP19A1 559/4885
US-20070185058-A1 Heteroaryl and benzyl amide compounds CYP1B1, CYP4B1, ABCG2 KIF11 3889/4885PTPN5 3932/4885CYP19A1 277/4885
US-11458149-B1 TEAD inhibitors and uses thereof TEAD2, TEAD3, TEAD4 KIF11 2459/4885PTPN5 1125/4885CYP19A1 559/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.